期刊
CELL
卷 140, 期 2, 页码 268-279出版社
CELL PRESS
DOI: 10.1016/j.cell.2009.12.046
关键词
-
资金
- Boehringer Ingelheim Fonds
- EC [QLG1-CT-2001-00869, LSHC-CT-2006-037731]
- Austrian Federal Government's GEN-AU [GZ 200.147/1-VI/1a/2006]
- Austrian Science Fund [FWF-P18421, FWF-P18782, SFB-23-B13, DK W1212]
- Boehringer Ingelheim Austria
- Austrian Science Fund (FWF) [W1212] Funding Source: Austrian Science Fund (FWF)
It is established that tumor cell-derived VEGF acts on endothelial cells to promote angiogenesis and tumor growth. Here, we demonstrate that in K5-SOS-dependent mouse skin tumors, autocrine VEGF is required for tumor cell proliferation in a cell-autonomous and angiogenesis-independent manner. VEGF is upregulated in SOS-expressing tumors, and its deletion in epidermal cells delays tumorigenesis by suppressing angiogenesis and tumor cell proliferation. Epidermis-specific Flt1 deletion also impairs tumorigenesis and proliferation. Surprisingly, complete tumor inhibition occurs in the absence of VEGF in EGFR mutant mice, demonstrating that VEGFR and EGFR synergize in neoplastic cells to promote tumor growth. Mechanistically, K5-SOS upregulates VEGF, Flt1, and Neuropilin-1 in an Erk-dependent manner, thereby activating an autocrine proliferation loop, whereas EGFR prevents tumor cells from apoptosis. Moreover, Flt1 is upregulated in human SCC, and its inhibition in SCC cells impairs proliferation. Thus, in addition to regulating angiogenesis, VEGF has to be considered as a potent growth factor for epidermal tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据